Table 3.
Comparison of immunophenotype response to radical prostatectomy in low- and high-risk patient groups.
| Low Risk | ||||
|---|---|---|---|---|
| Subset | PreOp (Cells/µL) Median (Range) |
Three Months (Cells/µL) Median (Range) | p Value | Trend |
| CD3+ | 1272 (930–1649) | 1433 (1139–2000) | <0.001 | ↑ |
| CD4+ | 779 (573–1207) | 887 (710–1228) | 0.15 | ≈ |
| CD8+ | 503 (356–711) | 692 (449–920) | <0.05 | ↑ |
| Ratio CD4+/CD8+ | 1.8 (1.1–2.4) | 1.5 (0.9–2.3) | <0.05 | ↓ |
| CD8+CD69+ | 185 (114–305) | 196 (152–278) | <0.001 | ↑ |
| Ratio CD4+/CD8+CD69+ | 4.5 (2.9–6.9) | 4.3 (3.0–7.0) | 0.33 | ≈ |
| CD4+CD25+FoxP3+ | 3.1 (1.6–5.6) | 3.3 (1.8–5.5) | 0.76 | ≈ |
| CD3-CD16+CD56+ | 232 (113–360) | 317 (176–484) | <0.05 | ↑ |
| MDSC | 11.9 (4.7–21.4) | 12.1 (6.0–21.7) | 0.12 | ≈ |
| CD19+ | 206 (119–337) | 189 (110–285) | 0.07 | ≈ |
| High Risk | ||||
| Subset |
PreOp (Cells/µL)
Median (Range) |
Three Months (Cells/µL)
Median (Range) |
p Value | Trend |
| CD3+ | 1426 (967–2161) | 1388 (1043–1852) | 0.11 | ≈ |
| CD4+ | 894 (587–1425) | 803 (683–1074) | 0.42 | ≈ |
| CD8+ | 571 (342–925) | 594 (405–920) | 0.24 | ≈ |
| Ratio CD4+/CD8+ | 1.6 (1.2–2.4) | 1.7 (1.0–2.1) | 0.81 | ≈ |
| CD8+CD69+ | 205 (120–373) | 227 (156–308) | <0.001 | ↑ |
| Ratio CD4+/CD8+CD69+ | 4.3 (3.0–7.1) | 3.9 (2.8–6.4) | 0.07 | ≈ |
| CD4+CD25+FoxP3+ | 4.6 (2.1–7.3) | 3.9 (2.4–7.1) | 0.11 | ≈ |
| CD3-CD16+CD56+ | 211 (119–320) | 328 (225–458) | 0.14 | ≈ |
| MDSC | 12.4 (6.5–19.9) | 16.2 (10.5–26.1) | <0.002 | ↑ |
| CD19+ | 188 (124–299) | 181 (147–272) | 0.50 | ≈ |
Symbols in Table 3: “≈”—no significant change; “↑”—increase; “↓”—decrease.